ChemoCentryx Regains Crohn’s Candidate Vercirnon From GSK
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK will continue development of a rheumatoid arthritis candidate optioned from ChemoCentryx in 2011 and is expected to decide before year’s end on whether to license a Phase II candidate for renal vasculitis from the California biotech.
You may also be interested in...
GSK/ChemoCentryx Crohn’s Failure May Sink Hefty Phase III Program
SHIELD-1 failure puts the entire 2,500-patient plus Phase III clinical program in limbo as GSK rethinks its Crohn’s disease approach and partner ChemoCentryx’s stock loses close to half its value.
ICER’s Final NASH Report Urges Step Therapy, Specialist Prescribing, Equitable Access
When the first non-alcoholic steatohepatitis drugs reach market, the health cost watchdog says payers will be justified in setting step-therapy including weight-management efforts, while early prescribing should be by specialists.
Ionis Finds Its Footing Ahead Of Its First Big Commercial Step
Ionis will launch its first commercial product through a co-commercialization agreement with AstraZeneca early next year, in preparation for its first wholly-owned drug launches soon to follow.